Rapid resource depletion on coral reefs disrupts competitor recognition processes among butterflyfish species.

Avoiding costly fights can help conserve energy needed to survive rapid environmental change. Competitor recognition processes help resolve contests without escalating to attack, yet we have limited understanding of how they are affected by resource depletion and potential effects on species coexistence. Using a mass coral mortality event as a natural experiment and 3770 field observations of butterflyfish encounters, we test how rapid resource depletion could disrupt recognition processes in butterflyfishes. Following resource loss, heterospecifics approached each other more closely before initiating aggression, fewer contests were resolved by signalling, and the energy invested in attacks was greater. By contrast, behaviour towards conspecifics did not change. As predicted by theory, conspecifics approached one another more closely and were more consistent in attack intensity yet, contrary to expectations, resolution of contests via signalling was more common among heterospecifics. Phylogenetic relatedness or body size did not predict these outcomes. Our results suggest that competitor recognition processes for heterospecifics became less accurate after mass coral mortality, which we hypothesize is due to altered resource overlaps following dietary shifts. Our work implies that competitor recognition is common among heterospecifics, and disruption of this system could lead to suboptimal decision-making, exacerbating sublethal impacts of food scarcity.

Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.

AIM: Radionuclide imaging of the HER2 receptor, which is a target for trastuzumab therapy, can provide important diagnostic information. Further, targeting radionuclide therapy might be an option for treatment of HER2 expressing tumors. The phage-display selected Affibody ligand Z(HER2:342), which binds to HER2 with an affinity of 22 pM, may here play an important role. The small size of the Z(HER2:342), 7.5 kDa, enables quick tumor localization and fast blood clearance. Earlier, successful targeting of HER2-expressing xenografts using Z(HER2:342) labeled using [(111)In]benzyl-DTPA was reported. By changing to the CHX-A''-DTPA chelator, the stability and labeling kinetics of the radiometal-Z(HER2:342) conjugate can be improved. The aim of this study was to evaluate the labeling of the CHX-A''-DTPA-Z(HER2:342) conjugate with (111)In for diagnostic imaging and with (114m)In for locoregional radionuclide therapy. METHODS: The isothiocyanate derivative of CHX-A''-DTPA was coupled to Z(HER2:342) in alkaline conditions at 37 degrees C. The conjugate was labeled with both (111)In and (114m)In and evaluated in vitro and in vivo. RESULTS: Labeling with (111)In and (114m)In provided >95% yield after 30 min at RT. Specific radioactivity was 0.5 and 12 MBq/nmol, for (114m)In and (111)In, respectively. The radiolabeled conjugates demonstrated specific binding to HER2 expressing SKOV-3 cells. In mice bearing SKOV-3 xenografts, the tumor uptake of [(111)In]CHX-A''-DTPA-Z(HER2:342) 4 h postinjection was 10.3+/-3.6% IA/g and tumor-to-blood ratio about 190. CONCLUSION: [(111)In]CHX-A''-DTPA-Z(HER2:342) is a promising candidate for the visualization of HER2 expression in malignant tumors. Labeled with (114m)In it could also be used for locoregional treatment of HER2 expressing tumors.

Gamma camera imaging of platinum in tumours and tissues of patients after administration of 191Pt-cisplatin.

The aim of this study was to visualize non-invasively the uptake of platinum in tumours and tissues after treatment with cisplatin. 191Pt-cisplatin was synthesized from 191PtCl4 with rigorous pharmaceutical quality control. The uptake of platinum by both tumorous and healthy tissues was studied by gamma camera imaging in 14 patients, 5 of whom showed a clear uptake of platinum in regions corresponding to known tumour sites. Maximum concentrations of platinum in the tumours were on average 4.9+/-1.0 microg/g, when normalized to an administered amount of 180 mg cisplatin. In all the patients, the liver was the organ that showed the highest uptake. Platinum uptake was also seen in the spleen, gall bladder, gastrointestinal tract, bladder, kidneys, ureter, neck and mediastinum and urogenital region. By using in-house production of 191Pt-cisplatin, it was possible to monitor the uptake of platinum in tumorous tissues and healthy organs.

110Sn/110In--a new generator system for positron emission tomography.

A generator system, 110Sn/110In, is suggested for use in the labelling of leukocytes with this short-lived (t1/2 = 1.15 h) positron emitting (62%) isotope of indium. The half-life gives the labelled leukocytes time to be adequately distributed but is short enough to allow repeated studies within a few hours. The mother radionuclide 110Sn (t1/2 = 4.15 h) is produced by the reaction natIn(p, xn)110Sn which has a maximum cross-section of 110 mb at approx. 70 MeV and a practical yield of 400 MBq/microAh.